Efficacy and Safety of Anticoagulants for COVID-19 Patients in the Intensive Care Unit: A Systematic Review and Meta-Analysis

Yulistiani1,2, Vina Neldi1, Budi Suprapti1,3, Alfian Nur Rosyid4,5

1Department of Pharmacy Practice, Faculty of Pharmacy, Airlangga University, Surabaya, East Java Indonesia; 2Master of Clinical Pharmacy Programme, Faculty of Pharmacy, Airlangga University, Surabaya, East Java, Indonesia; 3Department of Pharmacy, Universitas Airlangga Hospital, Surabaya, East Java, Indonesia; 4Department of Pulmonology, Universitas Airlangga Hospital, Surabaya, East Java, Indonesia; 5Medical Faculty, Universitas Airlangga, Surabaya, East Java, Indonesia

Corresponding author: Yulistiani, Department of Pharmacy Practice, Faculty of Pharmacy, Airlangga University, Surabaya, East Java Indonesia, Department of Pharmacy, Universitas Airlangga Hospital, Surabaya, East Java, Indonesia, TEL: +62 (031) 5933150; email: yulistiani@ff.unair.ac.id

Received, July 18, 2022; Revised, August 3, 2022; Accepted, August 12, 2022; Published, September 11, 2022

ABSTRACT—Purpose: This study aims to analyze the efficacy and safety of anticoagulants for COVID-19 patients in the intensive care unit. Methods: A comprehensive search was conducted using databases such as MEDLINE, PubMed, EuropePMC, Science Direct, Google Scholar, Clinicaltrial.gov, The Cochrane Central Register of Controlled Trial (CENTRAL, Cochrane Library) and several other published articles from the systematic review up to March 31, 2021. The Newcastle-Ottawa Scale (NOS) was used for the studies’ qualitative assessment. The primary outcome examined was mortality rate, while the secondary included the length of stay (LOS) in the ICU; hospital length of stay (HOS), coagulation markers including D-dimer, Platelet count, aPTT, PT and fibrinogen; markers of inflammation specifically C-reactive protein; and other adverse events ranging from hemorrhage to thrombosis. Additionally, the quantitative synthesis was conducted using fixed and random effects models in “The Revman 5.4”, while heterogeneity was tested using the I² measure. Results: A total of 1,062 articles were found during the initial search step and eventually 12 were chosen to be analyzed quantitatively in a meta-analysis. Comparison of the results related to anticoagulant group with no anticoagulant or standard care treatment showed that anticoagulant group significantly reduced mortality rate with RR= 0.53; 95 % CI, 0.30-0.95; P= 0.03, with I² = 88% and venous thromboembolism (VTE) RR = 0.53; 95% CI, 0.37-0.76; P = .0007 with I² =35%. Conclusions: Based on the results, anticoagulants can mitigate mortality rate and VTE in COVID-19 patients.

INTRODUCTION

The Coronavirus Disease 2019 (COVID-19) is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The virus was first identified in Wuhan, China in December 2019 (1,2). It was initially assumed that the virus can damage the respiratory system, but according to recent studies, SARS-CoV-2 also causes coagulation disorder namely COVID-19 Associated Coagulopathy or CAC (3–5). In a study of 184 critically ill COVID-19 patients in the intensive care unit (ICU), 31% were found to experience thrombotic complications (6). One of the most common complications is venous thromboembolism (VTE) with a prevalence of 27%, and the majority of cases are pulmonary embolism (6). Contrast-enhanced CT analysis in COVID-19 patients case series in the ICU showed a pulmonary artery thrombosis rate of 20.6% from 107 participants (7). In another study of 183 patients, 15 or 71.4% who died met the criteria for disseminated intravascular coagulopathy (DIC) based on the scoring system of the International Society of Thrombosis and Haemostasis (ISTH) with a score ≥ 5 (8). Meanwhile, Fogarty et al., found no signs of DIC, such as a significant decrease in platelets and fibrinogen in 83 patients (9).

The SARS-CoV-2 infection excessively increases the production of cytokines such as interferon and interleukin, causing a systemic inflammatory reaction known as a cytokine storm (10) which leads to systemic thrombus formation. Furthermore, this virus causes vascular endothelial damage associated with thrombogenesis (11). Aside from cytokine storm, COVID-19 patients also experience hypoxia characterized by vasoconstriction which reduces blood flow. Hypoxia plays a role in the pathogenesis of coagulopathy in COVID-19 patients causing a shift from antithrombotic and endothelial inflammation phenotypes into procoagulant and proinflammatory (11).

The process stated above can provoke
endotheliopathy where Von Willebrand Factor (vWF) are released and cause platelet aggregation, initiating microvascular thrombogenesis which leads to microthrombus formation. Platelets, monocytes, neutrophils, and microparticles adhere to the activated endothelium, which in turn trigger the coagulation cascade along with tissue factor (TF) and neutrophil extracellular traps (NETs). The increase in thrombin potentially causes of hypercoagulability (11) which worsens with the escalation of prothrombotic factors including Von Willebrand (vWF), VIII, fibrinogen, NETs, and thrombotic microparticles (12–14). Anticoagulant is one of several recommended therapies for COVID-19 patients (15). Besides, previous studies supported anticoagulant application as both therapy and prophylaxis. Anticoagulants potentially decrease coagulopathy, microthrombus, and organ damage (16), but there are still no general guidelines for their application in COVID-19 patients, and further studies are required to ensure effectiveness (17).

A study conducted by Tang et al. included 449 severe COVID-19 patients, a total of 99 were given heparin therapy for seven days or longer. Enoxaparin at a dose of 40-60 mg/day was also given to 94 patients, and 5 were given unfractionated heparin (UFH) at a dose of 10,000-15,000 units/day. The result showed no difference in the mortality rate of patients with heparin usage amounting to 30.3% and those without heparin usage 29.7% with p=0.910 on their 28th day. However, patients with ≥4 Sepsis-Induced Coagulopathy (SIC) showed a mortality rate drop on their 28th day with values of 40% and 62.9% for patients with and without heparin usage respectively (p=0.029). Patients with > 3.0 µg/mL D-dimer showed a 32.7% mortality rate if they were given heparin and 52.4% if they were not given heparin (p=0.017) (18,19).

Although several studies support the use of anticoagulants in COVID-19 patients, many also reported insignificant effects and the risk of hemorrhaging due to inappropriate anticoagulation. Recent investigations are needed to support the effectiveness of anticoagulation in COVID-19 patients. Therefore, this systematic review and meta-analysis aim to determine the efficacy and safety of anticoagulants for COVID-19 patients in the intensive care unit. The primary outcome is to determine whether anticoagulants affect the mortality in the patients.

The secondary outcomes are to determine whether anticoagulants affect: 1) length of stay (LOS) in the ICU, 2) hospital Length of Stay (HOS), 3) coagulation markers including D-dimer, platelet count, aPTT, PT, and fibrinogen; 4) inflammation markers specifically C-reactive protein, and 5) other adverse events such as hemorrhage and thrombosis. The systematic review protocol has been registered in PROSPERO (ID: CRD42021242877) entitled “Efficacy and Safety of Anticoagulant for COVID-19 Patients in Intensive Care Unit: A Systematic Review and Meta-Analysis”.

MATERIALS AND METHODS

Search Strategy

This systematic review and meta-analysis were carried out based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement. VN conducted a systematic literature search using the primary databases in MEDLINE, PubMed, EuropePMC, Science Direct, Google Scholar, and the Cochrane central register of controlled trial (CENTRAL, Cochrane Library). In addition to subscription databases, the team searched trial registries in ClinicalTrials.gov. The search was carried out up to March 30, 2021, with relevant keywords and controlled vocabulary were carefully selected without language restrictions as shown in Appendix I.

Eligibility Criteria

The PICOS model was used to select the study population, and the inclusion criteria include: 1) Patients: adult aged ≥ 18 years and diagnosed with severe COVID-19 in ICU, 2) Intervention: Studies that compared parenteral anticoagulant therapy such as Unfractionated heparin (UFH), Low Molecular Weight Heparin (LMWH), and Fondaparinux (FDP) with all appropriate doses and regimens both prophylactic and therapeutic, 3) Comparison: no anticoagulant or standard treatment, 4) Outcomes: primary outcomes was mortality, while secondary included length of stay (LOS) in the ICU, hospital Length of Stay (HOS), coagulation markers comprising D-dimer, platelet count, aPTT, PT, and fibrinogen; inflammation markers specifically C-reactive protein; other adverse events such as hemorrhage and thrombosis, and, 5) Study design: randomized controlled trials (RCTs), and observational studies. Meanwhile, the exclusion criteria were review articles, case-control studies, case reports and case series, studies with incomplete data, animal and unpublished studies including conference papers, theses, and expert opinions.

Selection of Studies and Data Extraction

Two authors (YL, BS) screened titles and abstracts to exclude irrelevant articles, then screening was carried out by reading the text thoroughly to assess
the article's suitability with the inclusion and exclusion criteria. When there are differences in their respective views, a joint discussion will be held by conferring with the third author (AN). Articles that met the inclusion criteria were then analyzed qualitatively, and the results were quantitatively analyzed (meta-analysis). Furthermore, the data were independently extracted by two authors (YL and BS) including patients’ demographics, first author, year of publication, country, design of the study, population, intervention, sample size, anticoagulant regimen administered involving type, dose, and duration of anticoagulant therapy; and all outcome measures.

Quality Assessment
Two independent authors (YL, VN) evaluated the methodological quality according to the Cochrane Collaboration’s tool. Any disagreements were resolved through discussion with the third author (AN). The quality assessment was carried out using the Newcastle Ottawa Scale (NOS) tool(20). NOS is a risk of bias (ROB) assessment tool for observational studies recommended by the Cochrane Collaboration (20). It is used for non-randomized studies in systematic review and/or meta-analyses based on 3 domains: the selection of the study groups; comparability; and the ascertainment of exposure and outcome for case-control or cohort studies, respectively. A maximum of 9 points can be assigned for the least risk of bias in these domains. The study quality is considered the lowest when the score is ≤ 4. Meanwhile, a study with a score of 5-6 is considered to have a moderate quality rate, while a score ≥ 7 is considered good/high quality (21).

Statistical Analysis
The meta-analysis was performed using the Review Manager Software (Revman), version 5.4 Windows. The effect estimation was in risk ratio (RR) for mortality and serious adverse events, as well as odds ratios (OR) for clinical improvement with 95% confidence intervals (CI). The pooled effect size estimation was performed by a fixed-effect or random-effect model after heterogeneity results were assessed. Furthermore, the heterogeneity was assessed using Cochran’s Q test and I² statistic with I² of <25% indicating no heterogeneity; 25-50% low; 50-75% moderate; and >75% high. Significant statistical heterogeneity was defined by a P<0.1 or I² >50%. When the P-value is defined by a P>0.1 or I² ≤ 50%, the fixed-effect model was used but when there is significant heterogeneity, the random-effect model was selected with I² >50% or P <0.1.

RESULTS

Study Results
A total of 1,062 studies were identified and 140 duplications were removed, hence, only 922 were screened. Among these, 71 were selected for full-text review after the irrelevant studies were removed. A total of 12 observational studies comprising 9 retrospective and 3 prospective were included in the meta-analysis. Studies were excluded after full-text review for the following reasons: 2 brief reports and letters to editor, 8 studies with different populations, 26 with unmatched eligibility, 7 with no comparing group, and 13 with inappropriate data. The PRISMA flowchart of study selection is depicted in Figure 1.

Study Characteristics
A total of 7,966 patients with a mean age between 60 to 70 years were analyzed in this meta-analysis. The most involved gender was male with 3,362, while females amounted to 1,831 and one study by Paranjpe did not attach the patients' gender (16). The participants involved consisted of certain races such as Caucasian, Asian, black, African American, Hispanic and all included studies were conducted on severe COVID-19 cases in the intensive care unit. Furthermore, multiple comorbidities were mentioned but the most common were hypertension, diabetes, pulmonary disorders, kidney, and cardiovascular diseases. The anticoagulants analyzed were Low Molecular Weight Heparin/LMWH including enoxaparin, nadroparin calcium, and fondaparinux; as well as Unfractionated Heparin (UFH). A total of 8 studies investigated the use of LMWH, especially enoxaparin, with prophylactic doses in 3 and therapeutic in 2, while both were examined in 3 studies. The use of UFH was reported in 3 studies consisted of therapeutic dose in 1 and prophylactic 2, while the use of nadroparin and fondaparinux was reported in 1 study, respectively. In addition, the most widely used anticoagulant with prophylactic doses was LMWH, especially enoxaparin. The characteristics of the included studies are presented in Table 1. Studies included were conducted in the United States (2,16,22,23), Italy (24,25), Turkey (26), France (27), and China (8,28–30).

Study Quality Assessment
The risk of bias was assessed using the NOS with 9 factors used to assess study quality. The results showed 3 studies (2,22,28) with high quality,
Figure 1. PRISMA flow chart and study selection process

3 with median quality (24,25,30) and 6 having low quality (8,16,23,26,27,29) (Table 2). The drawback of NOS in assessing the quality of studies is that there are no clear guidelines, making it possible for errors to occur in the assessment. Therefore, the evaluation must be carried out by more than one reviewer, and when there are differences in the evaluation, a joint discussion can be carried out. This tool has an adaptation index adjusted to the topic being assessed and provides a score ranging from 0-9, making it suitable for meta-regression analysis (31).

Meta-Analysis
In general, 7 studies reported a statistically significant association between anticoagulation administration and mortality. The random-effects model results indicated that the use of anticoagulants affected the relative risk of mortality with RR= 0.53; 95% CI, 0.30-0.95; and p = 0.03 as shown in Figure 2A. In this analysis, the random effect model was selected because heterogeneity of the studies was high at $I^2 = 88\%$. Regarding the secondary outcome, thrombotic events such as VTE was found in 6 studies while hemorrhage occurred in 1 study. Study outcomes related to coagulation markers including D-dimer, Platelet Count, aPTT, PT, and Fibrinogen; as well as inflammatory markers such as CRP were found in the baseline characteristics of each study. Furthermore, VTE was analyzed in the meta-analysis as a secondary outcome while hemorrhage was not assessed to avoid the risk of bias as the number of studies obtained was small. The fixed-effect model results showed that anticoagulant usage significantly reduced the risk of VTE compared to no anticoagulant or standard care treatment with $RR = 0.53$; 95% CI, 0.37-0.76; and $p = .0007$. The heterogeneity of the studies was low at $I^2 = 35\%$, while the forest plots of the 2 quantitatively analyzed outcomes are shown in Figures 2A and 2B. This analysis showed a statistically significant relationship with $p$-value < 0.05 between the administration of anticoagulants and the observed outcome.

DISCUSSION
This study was conducted to evaluate the current evidence on the efficacy and safety of anticoagulants for COVID-19 patients in the intensive care unit. The meta-analysis results showed that compared to no anticoagulant or standard care treatment, anticoagulant significantly affects mortality outcome and VTE. The current diagnosis of COVID-19 infection majorly uses the real-time reverse transcription-polymerase chain reaction (rRT-PCR), which is a standard test for
laboratory diagnosis. However, no RCT-based study was found during the search because it is still in the experimental stage. Each investigation has a different level of evidence with that of a systematic review depending on the study design. The primary study level is categorized based on the design from the highest to the lowest as follows: experimental; randomized or non-randomized controlled trials; quasi-experimental studies; and observational analytic studies including cohort and case-control.

Based on the variations between races, the results from each study cannot be generalized because racial differences can affect the outcome of a disease or the provision of specific therapies, one example is the variation of risk factors for VTE. A study reported that the incidence of VTE in an Asian population was in the low category with 21-29 cases per 100,000 individuals per year (32,33). Therefore, prophylactic anticoagulants such as LMWH might be considered with an adjusted dose. In this systematic review analysis, it was found that the use of anticoagulants is associated with the presence of coagulopathy in COVID-19 patients characterized by changes in several coagulation parameters such as D-dimer, platelet count, PT, and aPTT. The mechanism of coagulopathy in the COVID-19 pathophysiological process involves a procoagulant shift mechanism. An increase in the value of D-dimer was reported in COVID-19 patients, especially in those with severe symptoms and receiving treatments in the ICU (34). Moreover, an increase in the D-dimer value of more than 1 mg/dl is significantly associated with mortality (35).

According to Al-Samkari et al. (2020), 2/3 of most hemoi hemorrhaging events occur in patients receiving anticoagulants at therapeutic doses. The high mortality rate, especially in COVID-19 patients with critical conditions accompanied by hemorrhage, is an essential concern in the administration of anticoagulants. The results and stratification of patient groups are first considered before anticoagulant therapy is given. To date, guidelines for the administration of anticoagulants in COVID-19 patients have not been provided. They are currently still in the form of expert recommendations that require further studies (8,18,36–38). Meanwhile, the mechanism of anticoagulation in the COVID-19 treatment is related to the suppression of prothrombotic coagulopathy to prevent microvascular and macrovascular thrombosis. Several inflammatory markers such as C-reactive protein (CRP), erythrocyte sedimentation rate, procalcitonin, and ferritin reportedly increase in COVID-19 patients (39). Therefore, the administration of heparin (LMWH and UFH) is a profitable option because it provides anticoagulant and inflammatory effects such as neutralization of cytokines, chemokines, and extracellular histones (40). Heparin administration also reduces SARS-CoV-2 virus entry into cells through competitive binding with heparin sulfate on the host cell membranes (41).

These results support previous systematic reviews, stating that anticoagulants can reduce mortality and VTE.
Table 1. The characteristics of included studies

| Study                  | Study design/location                              | Participants | Mortality | Outcome | Intervention | NOS |
|------------------------|---------------------------------------------------|--------------|-----------|----------|--------------|-----|
|                        |                                                   |              | n (A vs B) | n (A vs B) | n (A vs B) |     |
|                        |                                                   |              | (A vs B)   | (A vs B)  | (A vs B)  |     |
| Al-Samkari et al (2)   | Multicenter Cohort prospective / United States    | 3239         | NA        | NA       | 305 vs 2934 | 7 vs 197 | 305 vs 2934 | 16 vs 74 | Enoxaparin or UFH | 8   |
| Baccellieri et al (24) | Single-centre Cohort prospective / Italy          | 200          | NA        | NA       | 17 vs 183  | 1 vs 28 | NA          | NA       | LMWH              | 6   |
| Canoglu & Saylan (26)  | Single-centre Retrospective / Turkey              | 154          | 56 vs 98  | 10 vs 44 | NA         | NA     | NA          | NA       | LMWH (Enoxaparin) | 3   |
| Falcone et al (25)     | Prospective Observational / Turkey                | 315          | 244 vs 71 | 38 vs 32 | NA         | NA     | NA          | NA       | LMWH (enoxaparin) | 6   |
| Fraissé et al (27)     | Mono-Center Cohort Retrospective / France         | 92           | NA        | NA       | 49 vs 43   | 20 vs 17 | NA          | NA       | Anticoagulant (no mention of AC) | 4   |
| Paranjpe et al (16)    | Cohort Retrospective / USA                        | 2773         | 786 vs 1987 | 177 vs 453 | NA         | NA     | NA          | NA       | Anticoagulant systemic (no mention of AC) | 4   |
| Shen et al (28)        | Multicenter Cohort Retrospective / China          | 89           | 67 vs 22  | 25 vs 14 | NA         | NA     | NA          | NA       | LMWH (enoxaparin) | 7   |
| Tang, Bai et al (8)    | Multicenter Cohort Retrospective / China          | 449          | 99 vs 350 | 30 vs 104 | NA         | NA     | NA          | NA       | LMWH (enoxaparin) or UFH | 4   |
| Tassiopoulos et al (22)| Single-centre Cohort Retrospective / New York     | 195          | 91 vs 104 | 25 vs 61 | 91 vs 104  | 9 vs 24 | NA          | NA       | Enoxaparin | 7   |
| Thondapu et al (23)    | Multi-Centre Cohort Retrospective Observational / United States | 138      | NA        | NA       | 126 vs 12  | 41 vs 3 | NA          | NA       | LMWH, Heparin | 4   |
| Yu et al (29)          | Single-Center Retrospective / China               | 142          | NA        | NA       | 37 vs 105  | 11 vs 39 | NA          | NA       | Anticoagulant (no mention of AC) | 3   |
| Zheng et al (30)       | Retrospective / China                            | 180          | 68 vs 112 | 39 vs 50 | NA         | NA     | NA          | NA       | Enoxaparin | 5   |

AC Anticoagulant, ICU intensive care unit, LMWH Low molecular weight heparin, NOS Newcastle Ottawa scale, UFH unfractionated heparin
## Table 2. Quality of Study based on Newcastle Ottawa Scale (NOS)

| Author/Year            | Representativeness of exposed cohort | Selection of non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at the start of the study | Comparability of cohorts based on the design or analysis | Assessment of outcome | Outcome follow-up length | Adequacy of follow-up of the cohort | Score total | Quality of study |
|------------------------|-------------------------------------|---------------------------------|---------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------|-----------------|
| Al-Samkari et al (2)   | 1                                   | 1                               | 1                         | 1                                                                                | 1                                                        | 1                    | 1                        | 1                     | 8          | High            |
| Baccellieri et al (24) | 0                                   | 0                               | 1                         | 1                                                                                | 1                                                        | 1                    | 1                        | 1                     | 6          | Median          |
| Canoglu & Saylan (26)  | 0                                   | 0                               | 0                         | 1                                                                                | 1                                                        | 1                    | 0                        | 0                     | 3          | Low             |
| Falcone et al (25)     | 0                                   | 0                               | 1                         | 1                                                                                | 1                                                        | 1                    | 1                        | 1                     | 6          | Median          |
| Fraissé et al (27)     | 0                                   | 1                               | 0                         | 0                                                                                | 1                                                        | 0                    | 1                        | 1                     | 4          | Low             |
| Paranjpe et al (16)    | 1                                   | 1                               | 0                         | 1                                                                                | 0                                                        | 0                    | 1                        | 0                     | 4          | Low             |
| Shen et al (28)        | 0                                   | 1                               | 0                         | 1                                                                                | 2                                                        | 1                    | 1                        | 1                     | 7          | High            |
| Tang, Bai et al (8)    | 0                                   | 1                               | 0                         | 1                                                                                | 0                                                        | 1                    | 1                        | 0                     | 4          | Low             |
| Tassiopoulos et al (22)| 0                                   | 1                               | 0                         | 1                                                                                | 2                                                        | 1                    | 1                        | 1                     | 7          | High            |
| Thondapu et al (23)    | 0                                   | 1                               | 0                         | 0                                                                                | 1                                                        | 1                    | 1                        | 0                     | 4          | Low             |
| Yu et al (29)          | 0                                   | 1                               | 0                         | 1                                                                                | 1                                                        | 1                    | 0                        | 0                     | 3          | Low             |
| Zheng et al (30)       | 1                                   | 1                               | 0                         | 0                                                                                | 1                                                        | 1                    | 1                        | 0                     | 5          | Median          |
This analysis found a significant effect between anticoagulation and VTE including Pulmonary embolism (PE) and/or Deep Vein Thrombosis (DVT) thrombotic events. The anticoagulant dose given between prophylactic and therapeutic did not show a significant difference. However, prescribed types and doses of anticoagulants have not been described in detail. Some studies explained that therapeutic anticoagulants can reduce mortality in COVID-19 patients but are associated with the risk of hemorrhage, while other investigations recommended using prophylactic anticoagulants, hence, further studies are needed regarding the dose of anticoagulation in COVID-19 patients.

Several studies reported persistent risk of VTE in some patients even after receiving anticoagulant prophylaxis. For example, Singhania et al., reported that 2/3 of COVID-19 patients admitted to the Intensive Care Unit (ICU) still had VTE complications despite prophylactic anticoagulation (42). In addition, in the post-mortem examination conducted by Menter et al., alveolar microthrombi 45% and glomerular microthrombus 16.7% were found in 21 patients (43). Another analysis conducted to determine the relationship between anticoagulant administration and mortality showed that anticoagulants are significant in reducing mortality in COVID-19 patients. This is also supported by several other studies showing that prophylactic anticoagulation can reduce mortality, especially in patients with elevated D-dimer values and those on mechanical ventilation (16,18).

Furthermore, Gonzales et al., reported a beneficial effect of anticoagulation in reducing mortality (44–46). Kamel et al. also confirmed the positive effects of anticoagulant application on the mortality rate of COVID-19 patients in hospitals with a steady association when made using a non-adjusted model (47). A systematic review reported by Moonla et al. showed a mortality rate reduction in patients receiving prophylactic anticoagulants compared to those who did not, with a 17% reduction. The example above has become a consideration in using prophylactic anticoagulants for COVID-19 patients. However, the safety of the anticoagulant must be considered when treating the patients. In the systematic review, two studies reported hemorrhaging events without significant data. Paranjpe et al. (16) found increased hemorrhage in COVID-19 patients receiving anticoagulant therapy, although it was not statistically significant. Therefore, stratification related to the need for anticoagulants, especially the administration of therapeutic doses in COVID-19 patients, is needed to provide maximum effectiveness and minimize side effects.

LIMITATIONS

This study has several limitations firstly, no randomized controlled trial was found, hence the design used was observational, both prospectively and retrospectively. Observational studies often use a limited number of populations, and the results provided are less representative of the general population. Second, there was no standard therapy for the use of anticoagulants in COVID-19 patients, making it difficult to determine the control group in the systematic review. Third, the development of the disease occurred very quickly, stating the need for more investigations. Fourth, several studies did not provide information regarding the type and dose of anticoagulant given hence, further subgroup analyses are needed.

CONCLUSION

Based on the systematic review and meta-analysis results, there is a relationship between anticoagulation administration, decreased mortality, and the incidence of VTE in COVID-19 patients. However, further studies are needed as there are no guidelines for the use of anticoagulants to achieve more effective and safer applications.

ACKNOWLEDGEMENT. The authors are grateful to the Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia, for the facilities.

CONFLICT OF INTEREST. All authors have no conflict of interest to disclose.

AUTHOR CONTRIBUTIONS. YL conceived and conceptualized the study idea. VN conducted comprehensive searches. YL and BS reviewed the search, performed the screening and full text assessment. AN resolved any conflicts. YL and VN completed the quality assessment and data extraction. YL performed the data analyses, VN and YL interpreted the results. YL and VN contributed to the draft manuscript. All authors contributed to the revisions and final proof reading.

FUNDING. This study received no specific grant from any funding agency in the public or commercial sector.

REFERENCES

1. Salamanna F, Landini MP, Fini M. Overt and non-overt disseminated intravascular coagulation and
the potential role of heparin in the COVID-19 pandemic outbreak. *Ther Adv Hematol.* 2020;11:204062072095165.
doi:10.1177/2040620720951655

2. Al-Samkari H, Gupta S, Leaf RK, et al. Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19. *Ann Intern Med.* January 2021;M20-6739.
doi:10.7326/M20-6739

3. Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. *Clin Chim Acta.* 2020;507(January):167-173.
doi:10.1016/j.cca.2020.04.027

4. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. *Lancet Haematol.* 2020;7(6):e438-e440. doi:10.1016/S2352-3026(20)30145-9

5. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *J Thromb Haemost.* 2020;18(5):1023-1026. doi:10.1111/jth.14810

6. Klok FA, Kruij MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res.* 2020;191(April):145-147. doi:10.1016/j.thromres.2020.04.013

7. Poissy J, Goutay J, Caplan M, et al. Pulmonary Embolism in Patients With COVID-19. *Circulation.* 2020;142(2):184-186. doi:10.1161/CIRCULATIONAHA.120.047430

8. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost.* 2020;18(5):1094-1099. doi:10.1111/jth.14817

9. Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID19 coagulopathy in Caucasian patients. *Br J Haematol.* 2020;189(6):1044-1049. doi:10.1111/bjh.16749

10. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet.* 2020;395(10229):1033-1034. doi:10.1016/S0140-6736(20)30628-0

11. Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. *Intensive Care Med.* 2020;46(8):1603-1606. doi:10.1007/s00134-020-06088-1

12. Lax SF, Skok K, Zechner P, et al. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome. *Ann Intern Med.* 2020;173(5):350-361. doi:10.7326/M20-2566

13. Panigada M, Bottino N, Tagliaabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. *J Thromb Haemost.* 2020;18(7):1738-1742. doi:10.1111/jth.14850

14. Wichmann D, Sperhake J-P, Lütgehetmann M, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. *Ann Intern Med.* 2020;173(4):268-277. doi:10.7326/M20-2003

15. Komiyama M, Hasegawa K. Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness. *Eur Cardiol Rev.* 2020;15:2019-2021. doi:10.15420/ecr.2020.24

16. Paranji A, Fuster V, Lala A, et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among hospitalized Patients With COVID-19. *J Am Coll Cardiol.* 2020;76(1):122-124. doi:10.1016/j.jacc.2020.05.001

17. McGovern R, Conway P, Pekrul I, Tujjar O. The Role of Therapeutic Anticoagulation in COVID-19. *Case Reports Crit Care.* 2020;2020:1-7. doi:10.1155/2020/8835627

18. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost.* 2020;18(4):844-847. doi:10.1111/jth.14768

19. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost.* 2020;18(5):1094-1099. doi:10.1111/jth.14817

20. Lo CKL, Mertz D, Loeb M. Newcastle-Ottawa Scale: Comparing reviewers’ to authors’ assessments. *BMC Med Res Methodol.* 2014;14(1):1-5. doi:10.1186/1471-2288-14-45/TABLES/1

21. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* 2010;25(9):603-605. doi:10.1007/s10654-010-9491-z

22. Tassiopoulos AK, Mofakhham S, Rubano JA, et al. D-Dimer-Driven Anticoagulation Reduces Mortality in Intubated COVID-19 Patients: A Cohort Study With a Propensity-Matched Analysis. *Front Med.* 2021;8(Feburary):1-10. doi:10.3389/fmed.2021.631335

23. Thondapu V, Montes D, Rosovsky R, et al. Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019. *J Vasc Surg Venous Lymphat Disord.* 2021;9(4):835-844.e4. doi:10.1016/j.jvs.2020.11.006

24. Baccellieri D, Bertoglio L, Apruzzi L, et al. Incidence of deep venous thrombosis in COVID-19 hospitalized patients during the first peak of the Italian outbreak. *Phlebol J Venous Dis.* November 2020;0268355520975599. doi:10.1177/0268355520975592
25. Falcone M, Tiseo G, Barbieri G, et al. Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study. *Open Forum Infect Dis.* 2020;7(12):1-9. doi:10.1093/ofid/ofaa563

26. Canoglu K, Saylan B. Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection. *Ann Saudi Med.* 2020;40(6):462-468. doi:10.1544/0256-4947.2020.462

27. Fraisse M, Logre E, Pajot O, Mentec H, Planteffè G, Contou D. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. *Crit Care.* 2020;24(1):275. doi:10.1186/s13054-020-03025-y

28. Shen L, Qiu L, Liu D, et al. The Association of Low Molecular Weight Heparin Use and Inhospital Mortality Among Patients Hospitalized with COVID-19. *Cardiovasc Drugs Ther.* 2021. doi:10.1007/s10557-020-07133-3

29. Yu Y, Tu J, Lei B, et al. Incidence and Risk Factors of Deep Vein Thrombosis in Hospitalized COVID-19 Patients. *Clin Appl Thromb.* 2020;26:107602962095321. doi:10.1177/1076029620953217

30. Zheng R, Zhou J, Song B, et al. COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU. *Exp Hematol Oncol.* 2021;10(1):6. doi:10.1186/s40164-021-00202-9

31. Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. *World J Meta-Analysis.* 2017;5(4):80. doi:10.13105/wjma.v5.i4.80

32. Stein PD, Kayali F, Olson RE, Milford CE. Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. *Am J Med.* 2004;116(7):435-442. doi:10.1016/j.amjmed.2003.11.020

33. Zakai NA, McClure LA, Judd SE, et al. D-dimer and the Risk of Stroke and Coronary Heart Disease. *Thromb Haemost.* 2017;117(03):618-624. doi:10.1160/TH16-07-0519

34. Shi C, Wang C, Wang H, et al. The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study. *Clin Transl Sci.* 2020;13(6):1087-1095. doi:10.1111/cts.12880

35. Garibaldi BT, Fiksel J, Muschelli J, et al. Patient Trajectories Among Persons Hospitalized for COVID-19. *Ann Intern Med.* 2021;174(1):33-41. doi:10.7326/M20-3905

36. Arachchilage DJ, Stacey A, Akor F, Scotz M, Laflan M. Thrombolysis restores perfusion in COVID-19 hypoxia. *Br J Haematol.* 2020;190(5):e270-e274. doi:10.1111/bjh.17050

37. Kollias A, Kyriakoulis KG, Dimakakos E, Poumakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. *Br J Haematol.* 2020;189(5):846-847. doi:10.1111/bjh.16727

38. Moores LK, Tritschler T, Bronsnahan S, et al. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. *Chest.* 2020;158(3):1143-1163. doi:10.1016/j.chest.2020.05.559

39. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. *Blood.* 2020;136(4):489-500. doi:10.1182/blood.202006520

40. Moonta C, Sosothikul D, Chiasakul T, Rojnuckarin P, Uaprasert N. Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. *Clin Appl Thromb.* 2021;27:1076029621100899. doi:10.1177/10760296211008999

41. Liu X, Zhang X, Xiao Y, et al. Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment. *medRxiv.* 2020. doi:10.1101/2020.04.23.2007685

42. Singhania N, Bansal S, Nimmatoori DP, Ejaz AA, McCullough PA, Singhania G. Current Overview on Hypercoagulability in COVID-19. *Am J Cardiovasc Drugs.* 2020;20(5):393-403. doi:10.1007/s40256-020-00431-z

43. Menter T, Haslbauer JD, Niemhold R, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. *Histopathology.* 2020;77(2):198-209. doi:10.1111/his.14134

44. Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in patients with Covid-19. *J Thromb Thrombolysis.* 2020;50(2):298-301. doi:10.1007/s11239-020-02162-z

45. Bousquet G, Falgarone G, Deutsch D, et al. ADL-dependency, D-Dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19. *Aging (Albany NY).* 2020;12(12):11306-11313. doi:10.18632/aging.103583

46. Gonzales-Porras J., Belhassen M, Lopez-Bernus A, Et.al. Low Molecular Weight Heparin in adults with COVID-19 infection. *Rev Med Virol.* 2021;31(3). doi:10.1002/rmv.2180

283
### Appendix I. Search Strategies

| Database       | Keywords                                                                 | Result |
|----------------|--------------------------------------------------------------------------|--------|
| PubMed         | (COVID-19* [tw] OR "SARS-CoV-2" [tw] OR "2019-nCoV" [tw] OR "severe acute respiratory syndrome coronavirus 2" [tw] OR "coronavirus SARS-CoV-2" [tw] OR "COVID-2019 pneumonia" [tw] OR 2019-nCoV AND (anticoagulants OR "anti coagulants" [tw] OR "anti coagulate" [tw] OR "anti coagulated" [tw]) AND "Intensive Care Units") | 121    |
| MEDLINE        | (COVID-19* [tw] OR "SARS-CoV-2" [tw] OR "2019-nCoV" [tw] OR "severe acute respiratory syndrome coronavirus 2" [tw] OR "coronavirus SARS-CoV-2" [tw] OR "COVID-2019 pneumonia" [tw] OR 2019-nCoV) AND ("anticoagulants" OR "anti coagulants" [tw] OR "anti coagulate" [tw] OR "anti coagulated" [tw]) OR "Heparin" OR "Unfractioned Heparin" OR UFH OR "Fondaparinux" OR "Enoxaparin") AND ("Intensive Care Units" OR "Critical Care Units") AND ("Randomized Controlled Trial" OR "Retrospective Studies" OR "Cohort Studies" OR "Observational Studies") | 137    |
| Science Direct | (COVID-19) AND (Anticoagulant OR Enoxaparin OR Fondaparinux OR Heparin) AND (Intensive Care Units OR Critical Illness) NOT Paediatric NOT Myocardial Infarction | 396    |
| Web Of Science | ((COVID-19 OR SARS-CoV-2) AND (anticoagulants OR Enoxaparin OR Fondaparinux OR Heparin) AND (Intensive Care Units OR Critical Illness OR Hospital Mortality)) | 182    |
| CENTRAL        | COVID-19 and anticoagulant                                              | 2      |
| Google Scholar | COVID-19 AND Anticoagulant OR Enoxaparin OR Fondaparinux OR Heparin AND Research Article | 119    |
| Europe PMC     | COVID-19 AND anticoagulants OR Heparin OR Enoxaparin OR Fondaparinux AND Intensive Care Units OR Critical Illness OR Hospital Mortality | 73     |
| other study    |                                                                         | 32     |